|Treatments:||Chemotherapy, Radiation||Hospital:||Centre Antoine-Lacassagne|
Patients: This Phase I study involved 43 patients with locally advanced or metastatic rectal cancer. Thirty-four patients were men, nine were women, and the median age was 59 years.
Treatment: The treatment consisted of radiotherapy and two chemotherapeutic agents: fluorouracil and oxaliplatin.
Toxicity: Grade 3-4 toxicities included anemia, thrombocytopenia, diarrhea, urinary tract toxicity, and asthenia.
Results: The median overall survival was not reported. Two complete responses and 19 partial responses were observed.
Support: Sanofi-Synthelabo financially supported this study. Sanofi-Synthelabo manufactures and/or markets oxaliplatin.
Correspondence: Eric Francois, MD